Detalle Publicación

ARTÍCULO
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
Autores: González Martín, Antonio; Gladieff, Laurence; Tholander, Bengt; Stroyakovsky, Daniel; Gore, Martin; Scambia, Giovanni; Kovalenko, Nadezhda; Oaknin, Ana; Ronco, Julian Perez; Freudensprung, Ulrich; Pignata, Sandro; OCTAVIA Investigators
Título de la revista: EUROPEAN JOURNAL OF CANCER
ISSN: 1879-0852
Volumen: 49
Número: 18
Páginas: 3831-3838
Fecha de publicación: 2013
Resumen:
OCTAVIA met its primary objective, demonstrating median PFS of approximately 2 years. This bevacizumab-containing regimen is active and tolerable.